文献速递冠心病血脂与心血管预防

FAME 3 试验:多支血管病变 CABG 与 PCI 的经济结局和生活质量对比

Economic Outcomes and Quality of Life After CABG or PCI for Multivessel Disease: The FAME 3 Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-10-25

FAME 3 随机试验纳入 1,500 例三支血管病变患者,比较 CABG 与血流储备分数(FFR)指导的 PCI(佐他莫司药物洗脱支架)5 年经济与生活质量结局。CABG 组 5 年累计费用高 30%(95%CI 16%-46%,P<0.001),QALYs 无显著差异;PCI 在 66% 的 bootstrap 重复中经济价值更优,CABG 的增量成本效果比在 98% 重复中超过 150,000 美元/QALY 基准。

要点

  • CABG 组 5 年累计费用较 PCI 组高 30%(95%CI 16%-46%,P<0.001)。
  • 5 年 QALYs 在 PCI 组(4.05±0.84)与 CABG 组(4.03±0.82)间无显著差异。
  • PCI 在 66% 的 bootstrap 重复中费用更低且 QALYs 更高,经济价值优于 CABG。

核心结论

  • 对于多支血管病变患者,FFR 指导的佐他莫司药物洗脱支架 PCI 较 CABG 提供显著更好的长期经济价值,临床结局相当且费用大幅降低。

研究设计与样本

  • FAME 3 随机试验纳入 1,500 例三支血管病变患者,随机分配至 CABG 或 FFR 指导的 PCI(佐他莫司药物洗脱支架),随访 5 年记录资源使用与生活质量。

主要发现

  • CABG 组 5 年累计费用较 PCI 组高 30%(95%CI 16%-46%,P<0.001)。
  • 5 年 QALYs 在 PCI 组(4.05±0.84)与 CABG 组(4.03±0.82)间无显著差异,但 PCI 后 EQ-5D 评分改善更快。
  • 入组时年龄<65 岁且分配至 PCI 的患者 5 年时就业率更高(56% vs 47%,P=0.025)。
  • PCI 在 66% 的 bootstrap 重复中费用更低且 QALYs 更高;CABG 的增量成本效果比在 98% 的 bootstrap 重复中超过 150,000 美元/QALY 基准。
  • 基于试验随访期结局的多种终生预测中,上述发现基本不变。

临床怎么用

  • 在多支血管病变血运重建决策中,可将 FFR 指导的 PCI 作为兼顾经济性与生活质量的选择,尤其适用于年轻患者。
  • 与 CABG 相比,PCI 可显著降低 5 年累计费用,且不牺牲 QALYs。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies have found coronary artery bypass grafting (CABG) to be cost-effective compared with percutaneous coronary intervention (PCI) among patients with multivessel coronary artery disease (CAD), but their comparative effectiveness and economic outcomes may have changed. OBJECTIVES: This study sought to compare the economic and quality of life outcomes of CABG vs PCI and determine their cost-effectiveness in the FAME (Fractional Flow Reserve vs Angiography for Multivessel Evaluation) 3 randomized trial. METHODS: FAME 3 randomly assigned 1,500 patients with 3-vessel CAD to either CABG or fractional flow reserve-guided PCI using zotarolimus drug-eluting stents. We documented resource use and quality of life over 5 years of follow-up. We calculated costs by applying Medicare reimbursement rates to resources used, assessed quality of life using the EuroQOL EQ-5D, calculated quality-adjusted life-years (QALYs) from EQ-5D utility values, and used multivariable regression to compare outcomes by treatment assignment. We calculated the incremental cost-effectiveness ratio based on 5-year outcomes and also on projected life expectancies, and assessed its variability in 10,000 bootstrap replications. RESULTS: Cumulative costs over 5 years were 30% higher in patients assigned to CABG (95% CI: 16%-46%; P < 0.001). QALYs over 5 years did not differ significantly between the PCI (4.05 ± 0.84) and CABG groups (4.03 ± 0.82), although EQ-5D scores improved more rapidly after PCI. Patients <65 years of age at enrollment assigned to PCI were more likely to be employed at 5 years (56% vs 47%; P = 0.025). PCI had greater economic value than CABG over 5 years, with lower costs and higher QALYs in 66% of replications, and incremental cost-effectiveness ratios for CABG above the $150,000/QALY benchmark in 98% of bootstrap replications. These findings were essentially unchanged in several lifetime projections based on the outcomes documented within the trial follow-up period. CONCLUSIONS: Fractional flow reserve-guided PCI using zotarolimus drug-eluting stents provides significantly better long-term value than CABG for treatment of patients with multivessel CAD, with equivalent clinical outcomes at substantially lower cost.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Hlatky MA, Ding VY, Zimmermann FM, et al. Economic Outcomes and Quality of Life After CABG or PCI for Multivessel Disease: The FAME 3 Trial. J Am Coll Cardiol. 2025. PMID: 41194756. doi:10.1016/j.jacc.2025.10.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。